Subscribe
shutterstock_393927661_marbury
marbury / Shutterstock.com
22 July 2022Big PharmaStaff writer

Competition watchdog fines big pharma duo £70m

The pair are rapped for overcharging the NHS | Unfair prices for an epilepsy drug lasted four years | Costs leapt from £2m to £50m in one year after the companies' “illegal exploitation” of market position.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Big Pharma
UK regulators no longer exempt from paying successful parties' costs
26 May 2022   The UK Supreme Court has ruled that regulators such as the Competition and Markets Authority should be required to pay the costs of a party successfully appealing against one of their infringement decisions.
Big Pharma
CMA costs case improves access to justice
30 June 2022   The UK Supreme Court ruling involving Pfizer and Flynn is important for any company considering an appeal against the regulator, say Sophie Lawrance and James Batsford of Bristows.
Big Pharma
Swiss watchdog investigates Novartis over patent use
20 September 2022   Authority carries out dawn raid at Novartis’ premises | Probe focuses on the alleged unlawful use of a skincare patent to bar competition


Editor's picks

Americas
UPC bans Meril Life Sciences from selling infringing heart valve
19 November 2024

Editor's picks

Americas
UPC bans Meril Life Sciences from selling infringing heart valve
19 November 2024
Americas
Big Pharma counsel embrace AI but data and legal risks loom
24 October 2024
Asia
President Xi sends message to AIPPI’s World Congress
22 October 2024
Unified Patent Court
‘Every CMS filing is painful’: Notes from a Unified Patent Court dispute
26 September 2024
Unified Patent Court
Interview: Klaus Grabinski, UPC Court of Appeal president
24 September 2024
Unified Patent Court
‘Be prepared, and don’t assume at the UPC’: Christopher Stothers
12 September 2024

More on this story

Big Pharma
UK regulators no longer exempt from paying successful parties' costs
26 May 2022   The UK Supreme Court has ruled that regulators such as the Competition and Markets Authority should be required to pay the costs of a party successfully appealing against one of their infringement decisions.
Big Pharma
CMA costs case improves access to justice
30 June 2022   The UK Supreme Court ruling involving Pfizer and Flynn is important for any company considering an appeal against the regulator, say Sophie Lawrance and James Batsford of Bristows.
Big Pharma
Swiss watchdog investigates Novartis over patent use
20 September 2022   Authority carries out dawn raid at Novartis’ premises | Probe focuses on the alleged unlawful use of a skincare patent to bar competition

More on this story

Big Pharma
UK regulators no longer exempt from paying successful parties' costs
26 May 2022   The UK Supreme Court has ruled that regulators such as the Competition and Markets Authority should be required to pay the costs of a party successfully appealing against one of their infringement decisions.
Big Pharma
CMA costs case improves access to justice
30 June 2022   The UK Supreme Court ruling involving Pfizer and Flynn is important for any company considering an appeal against the regulator, say Sophie Lawrance and James Batsford of Bristows.
Big Pharma
Swiss watchdog investigates Novartis over patent use
20 September 2022   Authority carries out dawn raid at Novartis’ premises | Probe focuses on the alleged unlawful use of a skincare patent to bar competition

More features

Bayer gains exclusive licence for heart drug in Japan
EPO delivers key Novo Nordisk, GSK and Inhibrx rulings
McGuireWoods expands team with ex-Novo Nordisk GC
Paul, Weiss swoops for senior duo from Weil, Gotshal
UPC bans Meril Life Sciences from selling infringing heart valve
SCOTUS denies Alvogen unit's appeal to sell Bausch Xifaxan generic
Kathi Vidal to rejoin previous firm as partner following USPTO departure
GSK triumphs in EPO appeal, revoking Pfizer patent